[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The United Bio-Technology (Hengqin) Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,63,83,108,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100641338","phase-3-phase-iii-study-of-ubt251-injection-in-patients-with-type-2-diabetes-mellitus-with-inadequate-glycemic-control-on-diet-and-exercise-aloneuniguide-1-100641338",false,"NCT07659574","Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）","A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）","UNIGUIDE-1","Inclusion Criteria:\n\n1. Aged 18-75 years (inclusive) at the time of signing the informed consent form (ICF), regardless of gender;\n2. Diagnosed with type 2 diabetes mellitus (T2DM) for at least 3 months in accordance with the 2019 World Health Organization (WHO) criteria;\n3. Managed solely through diet and exercise intervention (without the use of any glucose-lowering medications) for at least 3 months prior to screening;\n4. Glycated hemoglobin (HbA1c) level ≥7.5% and ≤10.5% at screening;\n5. Body mass index (BMI) ≥23.0 kg\u002Fm² at screening, and stable body weight (change \\\u003C5%, which may be based on the participant's self-report) within 3 months prior to screening;\n6. Trial participants (including their partners) have no plan for pregnancy from screening to 6 months after trial completion, and are willing to comply with the contraceptive measures specified in the trial, and have no plan for sperm or egg donation within 6 months after trial completion;\n7. Have been fully informed about this study and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Known history of hypersensitivity to this study drug, its drug product excipients, or other similar active drugs;\n2. History of medication use within 3 months prior to screening that meets any of the following conditions:\n\n1\\) Use of any glucose-lowering medications, including glucagon-like peptide-1 (GLP-1) analogues, oral antidiabetic drugs (OADs) (including but not limited to metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, glinides, sodium-glucose cotransporter 2 (SGLT-2) inhibitors), insulin (except for short-term use ≤14 days for acute conditions, such as perioperative or inpatient use), traditional Chinese medicines, or health supplements with glucose-lowering effects; 2) Use of medications that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc. (except for cumulative use \\\u003C7 days with the last dose administered more than 7 half-lives prior to the first day of screening); 3) Use of weight-loss medications (including but not limited to orlistat, liraglutide, or other similar prescription or over-the-counter medications for weight loss); 3.History or evidence of any of the following diseases:\n\n1. Diagnosis of other types of diabetes: such as type 1 diabetes mellitus (T1DM), other specific types of diabetes (e.g., genetic defects in beta-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, etc.);\n2. History of acute or chronic pancreatitis, or pancreatic surgery;\n3. History of symptomatic gallbladder disease within 1 year before screening (excluding trial participants who have undergone cholecystectomy \\[completed at least 3 months before screening\\] without long-term complications), or abdominal ultrasound at screening indicating large gallstones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the study physician determines may affect trial participant safety;\n4. Personal or family history (within first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n5. History of hematological disorders that may affect HbA1c test results or increase the risk to trial participants (e.g., aplastic anemia, myelodysplastic syndromes, etc.), or any diseases causing hemolysis or erythrocyte instability (e.g., sickle cell disease, thalassemia, etc.);\n6. History of moderate to severe depression or severe psychiatric disorders (including but not limited to suicidal ideation or attempt, schizophrenia, bipolar disorder, etc.);\n7. History of clinically significant cardiovascular or cerebrovascular disease within 6 months before screening\n8. Severe retinal or macular disease (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) at screening or in the past, requiring urgent treatment as determined by the study physician;\n9. Severe hypoglycemia (hypoglycemia accompanied by severe cognitive impairment requiring assistance from others to recover) or recurrent symptomatic hypoglycemia (≥2 episodes in 6 months) within 6 months prior to screening;\n10. History of acute metabolic complications of diabetes (including but not limited to diabetic ketoacidosis \\[DKA\\], hyperosmolar hyperglycemic state \\[HHS\\] requiring hospitalization, hyperosmolar coma, lactic acidosis, etc.) or diabetic foot within 6 months prior to screening;\n11. History of malignancy; 4.Blood loss ≥400 mL (including trauma, blood draw, blood donation) within 3 months before screening, or receipt of blood or blood component transfusion; 5.Lactating women or pregnant women;","ALL","18 Years","75 Years",{"count":21,"type":22},360,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control on diet and exercise alone",[28],"Type 2 Diabetes","NOT_YET_RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":22},"2026-08-10",{"date":37,"type":22},"2027-10-22",{"name":39,"class":40},"The United Bio-Technology (Hengqin) Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100641845","phase-3-phase-iii-study-of-ubt251-injection-in-patients-with-type-2-diabetes-with-inadequate-glycemic-control-on-metformin--sulfonylureasglt2-inhibitor-therapy-uniguide-2-100641845","NCT07653477","Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea\u002FSGLT2 Inhibitor Therapy (UNIGUIDE-2)","A Multicenter, Randomized, Open-Label, Semaglutide Injection-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With Metformin Alone or in Combination With Sulfonylurea\u002FSodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Therapy (UNIGUIDE-2)","UNIGUIDE-2","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive) at the time of signing informed consent, with no restriction on gender;\n* Diagnosed with Type 2 Diabetes Mellitus (T2DM) according to the 2019 World Health Organization (WHO) criteria (Appendix 1), with glycated hemoglobin (HbA1c) ≥7.5% and ≤11.0%;\n* Participants with inadequate glycemic control despite stable treatment for 3 months prior to screening with 1) metformin; or 2) metformin in combination with sulfonylurea; or 3) metformin in combination with sodium-glucose cotransporter 2 (SGLT2) inhibitor, with the following dosage requirements:\n\nMetformin: ≥1500 mg\u002Fday or maximum tolerated dose (at least ≥1000 mg\u002Fday); Sulfonylurea: half of the maximum daily dose as specified in the package insert or maximum tolerated dose (see Appendix 2 for details); SGLT2 inhibitor: daily dose approved in the package insert (see Appendix 2 for specific products and dosage requirements).\n\n* Body mass index (BMI) ≥23.0 kg\u002Fm² at screening, with stable body weight for 3 months prior to screening (change \\\u003C5%, based on participant's report);\n* Participants (including their partners) with no plan for pregnancy from screening until 6 months after completion of the study, willing to use contraceptive measures, and with no plan to donate sperm or ova within 6 months after study completion;\n* Participants who have been fully informed about the study and have voluntarily signed written informed consent.\n\nExclusion Criteria:\n\n* Known history of hypersensitivity to the investigational medicinal product or its excipients or other similar active drugs;\n* Treatment with any of the following medications within 3 months prior to screening:\n\n  1. Other antidiabetic medications except background therapy (short-term insulin use ≤14 days for acute conditions is allowed, e.g., perioperative period or hospitalization);\n  2. Medications that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc. (excluded if cumulative use \\\u003C7 days and the end of treatment is \\>7 half-lives prior to the first day of screening);\n  3. Weight-loss medications (including but not limited to orlistat, semaglutide, or other similar prescription or over-the-counter drugs for weight loss).\n* History or evidence of any of the following diseases:\n\n  1. Diagnosis of other types of diabetes: such as Type 1 diabetes mellitus, special types of diabetes (e.g., genetic defects in β-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, etc.);\n  2. History of acute or chronic pancreatitis, or pancreatic surgery;\n  3. History of symptomatic gallbladder disease within 1 year prior to screening (participants who have undergone cholecystectomy \\[completed at least 3 months prior to screening\\] without long-term complications are excluded); or abdominal ultrasound at screening indicating large gallbladder stones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the investigator comprehensively determines may affect participant safety;\n  4. Personal or family history (first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n  5. History of hematological disorders that may affect HbA1c test results or increase participant risk (e.g., aplastic anemia, myelodysplastic syndrome, etc.), or any disease causing hemolysis or red blood cell instability (e.g., sickle cell disease, thalassemia, etc.);\n  6. History of moderate to severe depression or history of severe psychiatric disorders (including but not limited to suicidal ideation or suicide attempt, schizophrenia, bipolar disorder, etc.);\n  7. History of clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening, defined as:\n\n     1. Myocardial infarction (MI) or unstable angina;\n     2. Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention);\n     3. Congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV) (see Appendix 3 for details);\n     4. Cerebrovascular accident (excluding old lacunar infarction), including but not limited to hemorrhagic or ischemic stroke or transient ischemic attack;\n     5. Other cardiovascular or cerebrovascular diseases assessed by the investigator as unsuitable for participation in this study;\n  8. Severe retinal or macular lesions at screening (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.), and the investigator determines that further urgent treatment is required;\n  9. Severe hypoglycemia (hypoglycemia with severe cognitive impairment requiring other therapeutic measures to assist recovery) or recurrent symptomatic hypoglycemia (≥2 times within 6 months) within 6 months prior to screening;\n  10. History of acute metabolic complications of diabetes (including but not limited to diabetic ketoacidosis, hyperosmolar hyperglycemic state requiring hospitalization, hyperosmolar coma, lactic acidosis, etc.) or diabetic foot within 6 months prior to screening;\n  11. Concurrent gastrointestinal emptying disorders (e.g., gastroparesis, pyloric obstruction, intestinal obstruction, etc.) at screening, gastrointestinal diseases assessed by the investigator as increasing risk after administration (e.g., severe active ulcer, inflammatory bowel disease, acute gastroenteritis, uncontrolled gastroesophageal reflux disease, etc.), or history of major gastrointestinal surgery (gastrointestinal polypectomy, appendectomy, cholecystectomy, etc. that have completely recovered and are assessed by the investigator as not affecting study safety are excluded);\n  12. Major surgery, severe trauma, or severe infection within 1 month prior to screening, assessed by the investigator as unsuitable for participation in this study;\n  13. History of malignant tumors (excluding adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, ductal carcinoma in situ of the breast after radical surgery, and assessed by the investigator as currently stable);\n  14. Concurrent other diseases, such as respiratory, urinary, neurological, hematological, immune system diseases, etc., and the investigator considers that they affect participant safety, efficacy evaluation, or compliance.\n* Screening results showing any of the following abnormal findings:\n\n  1. Hepatic or renal impairment: serum alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≥3× upper limit of normal (ULN); serum total bilirubin (TBIL) ≥1.5×ULN; estimated glomerular filtration rate (eGFR) \\\u003C45 mL·min-¹·1.73m-² (calculated according to the CKD-EPI 2021 equation, see Appendix 4);\n  2. Serum calcitonin ≥50 pg\u002FmL (i.e., 50 ng\u002FL);\n  3. Thyroid dysfunction not controlled with stable drug dosage, or clinically significant abnormalities in thyroid function test results at screening requiring initiation of treatment, or thyroid ultrasound at screening indicating thyroid nodules ≥TI-RADS 4a (or ≥TR4 according to the US classification standard) or assessed by the investigator as possibly requiring biopsy and\u002For surgery during the study period;\n  4. Fasting triglycerides ≥5.6 mmol\u002FL;\n  5. Serum amylase and\u002For lipase \\>2.0×ULN;\n  6. International normalized ratio (INR) above the upper limit of the normal range;\n  7. Hemoglobin \\\u003C100 g\u002FL;\n  8. Untreated or poorly controlled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg, based on the mean of 3 blood pressure measurements during the screening period);\n  9. Clinically significant electrocardiogram (ECG) abnormalities, such as:\n\n     1. Second-degree or third-degree atrioventricular block;\n     2. Long QT syndrome, or QT interval corrected using Fridericia's formula (QTcF) \\>470 ms for female participants or \\>450 ms for male participants (calculation formula see Appendix 5);\n     3. Pre-excitation syndrome (Wolff-Parkinson-White syndrome);\n     4. Heart rate \\\u003C50 beats\u002Fmin or \\>100 beats\u002Fmin;\n     5. Other serious arrhythmias requiring treatment;\n  10. Positive hepatitis B surface antigen with hepatitis B virus deoxyribonucleic acid (HBV-DNA) exceeding the upper limit of the reference range, or positive hepatitis C virus antibody with hepatitis C virus ribonucleic acid (HCV-RNA) exceeding the upper limit of the reference range, or positive human immunodeficiency virus (HIV) antibody, or positive both specific and non-specific syphilis antibodies;\n  11. Abnormalities in physical examination, vital signs, laboratory tests, etc. that are clinically significant and assessed by the investigator as potentially posing significant risk to participants or interfering with the evaluation of safety, PK, or PD results, making them unsuitable for participation in this study.\n* Participation in other interventional clinical trials within 3 months prior to screening (excluding those who only participated in screening but were not enrolled, or those who were enrolled but did not receive treatment);\n* Blood loss ≥400 mL (including trauma, blood draw, blood donation) within 3 months before screening, or receipt of blood or blood component transfusion;\n* Lactating women or pregnant women;",{"count":51,"type":22},956,[25],"This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide Injection after 36 weeks of continuous administration in study participants with Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control on oral antidiabetic medications.A total of 956 participants are planned to be enrolled, including the UBT251 Injection 2 mg group, 4 mg group, 6 mg group, and Semaglutide group，with an approximate study duration of 58 weeks per participant.",[28],"2026-06-12",{"date":57,"type":33},"2026-06-17",{"date":59,"type":22},"2026-07-30",{"date":61,"type":22},"2028-02-29",{"name":39,"class":40},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},"100642121","phase-3-ubt251-injection-phase--study-overweight-or-obesity-100642121","NCT07648225","UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)","A PhaseⅢ Study to Evaluate the Efficacy and Safety of UBT251 Injection in Overweight\u002FObese Patients","Inclusion Criteria：\n\n1. Age 18-75 years (inclusive) at the time of signing the informed consent form, regardless of gender;\n2. Body mass index (BMI) ≥28.0 kg\u002Fm² (obesity) or 24.0 kg\u002Fm² ≤ BMI \\\u003C28.0 kg\u002Fm² (overweight) at screening, accompanied by by at least one of the following: a. Prediabetes, hypertension, dyslipidemia, or fatty liver; b. Weight-bearing joint pain; c. Obesity-induced dyspnea or obstructive sleep apnea syndrome;\n3. Self-reported having been on diet and exercise control for 3 months or more prior to screening, with body weight change ≤5 kg within the past 3 months;\n4. Trial participants (including their partners) have no plan for pregnancy from screening to 6 months after trial completion, and are willing to comply with the contraceptive measures specified in the trial, and have no plan for sperm or egg donation within 6 months after trial completion;\n5. Have been fully informed about this study and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Known history of hypersensitivity to this study drug, its drug product excipients, or other similar active drugs;\n2. Any of the following medication history within 3 months before randomization:\n\n   1. Treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors, amylin analogs, glucagon-like peptide-1 (GLP-1) analogs, glucose-dependent insulinotropic polypeptide (GIP) analogs, or glucagon (GCG) analogs;\n   2. Use of over-the-counter weight-loss medications or appetite suppressants (including traditional Chinese medicine, dietary supplements, meal replacements), or prescription weight-loss medications (including but not limited to orlistat) or lipolytic injections (e.g., fat-dissolving injections);\n   3. Use of medications that may affect body weight for a duration of 1 week or longer, or anticipated use during the trial, including but not limited to systemic glucocorticoid therapy (intravenous or oral administration, except for the following: topical external use or intra-articular, intranasal, ophthalmic, and inhaled glucocorticoids; short-term \\[≤7 days\\] systemic glucocorticoid use for prevention or treatment of non-autoimmune allergic diseases, upper respiratory tract infection);\n   4. Treatment with tricyclic antidepressants, antipsychotics, or antiepileptic medications;\n   5. Treatment with antidiabetic medications;\n3. History or evidence of any of the following diseases:\n\n   1. Diagnosis of type 1, type 2 diabetes mellitus, or other types of diabetes mellitus (excluding history of gestational diabetes mellitus);\n   2. Secondary obesity caused by diseases (including but not limited to elevated cortisol hormones \\[e.g., Cushing's syndrome\\], pituitary\u002Fhypothalamic injury, hypothyroidism, etc.) or medications (including but not limited to long-term glucocorticoid use, antidepressants, etc.);\n   3. History of acute or chronic pancreatitis, or pancreatic surgery;\n   4. History of symptomatic gallbladder disease within 1 year before screening (excluding trial participants who have undergone cholecystectomy \\[completed at least 3 months before screening\\] without long-term complications), or abdominal ultrasound at screening indicating large gallstones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the study physician determines may affect trial participant safety;\n   5. Personal or family history (within first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n   6. Planned bariatric surgery during the trial or history of bariatric surgery, except for the following: a) acupuncture for weight loss or liposuction (e.g., abdominal liposuction) performed \\>1 year before screening; b) gastric banding, but the band was removed \\>1 year before screening; c) intragastric balloon, but the balloon was removed \\>1 year before screening; d) duodenal-jejunal bypass liner, but the liner was removed \\>1 year before screening;\n   7. History of depression or severe mental illness (including but not limited to suicidal tendencies, schizophrenia, bipolar disorder, etc.);\n   8. History of clinically significant cardiovascular or cerebrovascular disease within 6 months before screening;\n   9. Severe retinal or macular disease (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) at screening or in the past, requiring urgent treatment as determined by the study physician;\n   10. History of malignancy;\n4. Blood loss ≥400 mL (including trauma, blood draw, blood donation) within 3 months before screening, or receipt of blood or blood component transfusion;\n5. Lactating women or pregnant women;",{"count":71,"type":22},600,[25],"This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight\u002Fobese patients",[75],"Obesity & Overweight","2026-06-09",{"date":30,"type":33},{"date":79,"type":22},"2026-07-31",{"date":81,"type":22},"2027-11-03",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100638341","phase-1-a-phase-i-study-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-single-subcutaneous-ubt38006-injection-in-healthy-adult-males-100638341","NCT07630233","A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of UBT38006 Injection in Healthy Adult Male Subjects","Inclusion Criteria:\n\n* Aged 18-45 years (inclusive) at the time of informed consent form (ICF) signing;\n* Sex: Male;\n* Body weight ≥50.0 kg and body mass index (BMI) between 19.0-24.0 kg\u002Fm² (BMI = weight \\[kg\\] \u002F height² \\[m²\\]), inclusive, at Screening;\n* Fasting plasma glucose (FPG) between 3.9-6.1 mmol\u002FL (exclusive of boundary values) at Screening; 2-hour plasma glucose \\\u003C7.8 mmol\u002FL on oral glucose tolerance test (OGTT) at Screening; insulin release test (IRT) results normal, or abnormal but judged by the Investigator as not clinically significant (NCS)at Screening; glycated hemoglobin (HbA1c) ≤6.0% at Screening;\n* The subject (including his partner) is willing to use adequate and effective contraception voluntarily from Screening through 3 months after administration of the investigational medicinal product (IMP) (see Appendix 2 for details), and has no plan to donate sperm within 3 months after IMP administration;\n* The subject is able to communicate well with the Investigator, has adequate understanding of this study, participates voluntarily, understands and complies with all study requirements, and provides written informed consent.\n\nExclusion Criteria:\n\n* History of severe hypersensitivity (e.g., allergy to three or more allergens, allergic asthma involving the lower respiratory tract, or allergy requiring systemic corticosteroid therapy) or known hypersensitivity to any component of the investigational medicinal product;\n* History of severe or currently clinically significant disease\u002Fcondition (including but not limited to diseases of the nervous, cardiovascular, respiratory, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, metabolic, and skeletal systems, history of malignancy, or neurological or psychiatric disease\u002Fcondition);\n* History of orthostatic hypotension, syncope, or amaurosis, or first-degree relative with history of diabetes mellitus;\n* Laboratory abnormalities (hematology, blood chemistry, coagulation function, thyroid function, urinalysis, stool routine, etc.) at Screening that are judged by the Investigator as clinically significant;\n* Positive insulin autoantibody (IAA) at Screening;\n* Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody, or Treponema pallidum antibody at Screening;\n* History of drug abuse, or positive urine drug screen prior to randomization;\n* Clinically significant abnormalities on physical examination, electrocardiogram (ECG), or vital signs (body temperature, pulse, blood pressure);\n* Use of insulin-containing agents within 3 months prior to dosing, or use of any other medication (including traditional Chinese medicine, over-the-counter drugs, etc.) within 30 days prior to dosing;\n* Vaccination with any vaccine within 1 month prior to dosing;\n* History of surgery within 3 months prior to dosing, or planned surgery during the entire study period;\n* History of blood loss or blood donation exceeding 200 mL within 3 months prior to dosing (calculated from the day before dosing);\n* Hemoglobin below the lower limit of normal (LLN);\n* Participation in other interventional clinical trials within 3 months prior to dosing (except for subjects who only underwent screening but were not enrolled, or were enrolled but did not receive treatment);",true,"MALE","45 Years",{"count":94,"type":22},43,[96],"PHASE1","This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design. Insulin degludec injection serves as the active control and is administered in an open-label manner.\n\nThe study will be conducted across 5 cohorts, comprising 4 dose-escalation cohorts of UBT38006 (1, 3, 6, and 12 nmol\u002Fkg) and 1 active control cohort of insulin degludec (0.4 U\u002Fkg \\[2.4 nmol\u002Fkg\\]). The safety and tolerability (including local tolerability) as well as the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single subcutaneous doses of UBT38006 injection will be evaluated in healthy adult male subjects.\n\nIn Cohort 1 (1 nmol\u002Fkg), subjects will be randomized in a 4:1 ratio to receive either UBT38006 injection or placebo. In Cohorts 2-4 (3, 6, and 12 nmol\u002Fkg), subjects will be randomized in an 8:2 ratio to receive the corresponding dose of UBT38006 injection or placebo. Subjects in Cohort 5 (insulin degludec active control) will receive 0.4 U\u002Fkg (2.4 nmol\u002Fkg) insulin degludec injection. Cohorts 1-4 will follow a double-blind design, while Cohort 5 will be open-label.",[99],"Type 2 Diabetes Mellitus (T2DM)","2026-06-01",{"date":102,"type":33},"2026-06-05",{"date":104,"type":22},"2026-06-19",{"date":106,"type":22},"2026-10-25",{"name":39,"class":40},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100604102","phase-2-a-study-of-ubt251-in-participants-with-metabolic-dysfunction-associated-steatohepatitis-mash-100604102","NCT07145151","A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)","MASH","Inclusion Criteria:\n\nAge 18-75 years (inclusive) at screening; sex unrestricted.\n\nSubjects with centrally confirmed MASH (metabolic dysfunction-associated steatohepatitis) based on liver histopathology must meet all the following criteria:\n\n1. NAS (Appendix 1) ≥ 4 （with at least 1 point each for lobular inflammation and ballooning degeneration）;\n2. CRN fibrosis stage (see Appendix 2) of F2 or F3 (a liver biopsy obtained ≤ 6 months before screening is acceptable if it meets the above criteria).\n\n3.Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥ 8 % at screening (MRI-PDFF results obtained within 2 months prior to screening at the trial site are acceptable).\n\n4.Subjects must have \\\u003C5% body weight fluctuation during the 6 weeks prior to randomization (based on self-reported data), calculated as: \\[(Highest weight - Lowest weight) \u002F Highest weight\\] × 100%. For subjects using historical liver biopsy, documented weight change from biopsy to randomization must also be \\\u003C 5 %.\n\n5.At least one cardiometabolic risk factor at screening:\n\n1. Body mass index (BMI) ≥ 24.0 kg\u002Fm², or waist circumference ≥90 cm for males or ≥85 cm for females;\n2. Blood pressure ≥ 130\u002F85 mmHg, or on antihypertensive therapy;\n3. Fasting triglycerides ≥ 1.70 mmol\u002FL and \\\u003C 5.6 mmol\u002FL, or on lipid-lowering therapy;\n4. Fasting HDL-C ≤ 1.0 mmol\u002FL for males or ≤ 1.3 mmol\u002FL for females; or on lipid-lowering therapy;\n5. Fasting glucose ≥ 6.1 mmol\u002FL or glycated hemoglobin (HbA1c) ≥ 5.7 %, or documented history of type 2 diabetes mellitus (T2DM), or Homeostatic Model Assessment of Insulin Resistance index ≥ 2.5.\n\n6.Subjects with type 2 diabetes mellitus (T2DM) must meet glycated hemoglobin (HbA1c) ≤ 9.0 % at screening (local result obtained ≤ 2 weeks before randomization accepted), and stable glycemic control regimen for at least 3 months prior to screening: subjects must be on diet and exercise control alone, or in combination with stable-dose glucose-lowering medications, with the following requirements::\n\n1. Diet and exercise alone;\n2. Stable-dose use of metformin, sulfonylureas, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or insulin, stable insulin dose defined as ≤35% variation in total daily insulin dose; 7. Subjects (including partners) must have no pregnancy plans from screening through 6 months post-trial and must practice contraception during the study, with no plans to donate sperm\u002Foocytes for 6 months after trial completion.\n\n8\\. Subjects must provide informed consent prior to trial participation and voluntarily sign the written informed consent form.\n\n9.Voluntarily comply with all trial follow-up requirements, demonstrate good protocol adherence, and be willing and able to undergo protocol-specified liver biopsies.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to the investigational product or any of its excipients, or allergy to other GLP-1 receptor agonists, or clinically significant history of multiple\u002Fsevere drug allergies, or current allergic diseases or hypersensitivity diathesis;\n2. Previous use of any of the following drugs or treatments:\n\n1\\) Use of GLP-1 receptor agonists (GLP-1R), or GLP-1R\u002FGCGR agonists, or GLP-1R\u002FGIPR\u002FGCGR agonists within 3 months prior to screening; 2) Cumulative use for ≥4 weeks within 3 months prior to screening, use within 1 month prior to screening, or planned use during the trial of vitamin E (dose \\>400 IU\u002Fday), thiazolidinediones, polyunsaturated fatty acids, or ursodeoxycholic acid; 3) Cumulative use for ≥4 weeks within 3 months prior to screening, use within 1 month prior to screening, or planned use during the trial of drugs associated with liver injury, hepatic steatosis, or steatohepatitis: including amiodarone, methotrexate, systemic glucocorticoids (dose \\>5 mg\u002Fday prednisone equivalent), estrogens (dose exceeding hormone replacement therapy or contraceptive use), tetracyclines, tamoxifen, anabolic steroids, valproate, or restricted drugs, or any drug deemed likely to interfere with efficacy or safety evaluations; 4) Unstable doses of statins, fibrates, or PCSK9 inhibitors within 1 month prior to screening; 3.History or evidence of any of the following diseases:\n\n1. Chronic liver disease other than MASH (e.g., autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, chronic liver disease-related ascites, esophageal varices, hepatic encephalopathy, etc.).\n2. Diagnosis of type 1 diabetes or other specific types of diabetes, except resolved gestational diabetes;\n3. Acute pancreatitis or chronic pancreatitis within 1 year prior to screening, history of pancreatic surgery; or symptomatic gallbladder disease within 1 year prior to screening (e.g., choledocholithiasis, multiple gallstones, etc., except those who underwent cholecystectomy or stone removal);\n4. Personal or family history (first-degree relatives-parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);\n5. History of severe psychiatric disorders, including but not limited to depression, suicidal tendencies or attempts, schizophrenia, bipolar disorder, etc.;\n6. Clinically significant active cardiovascular\u002Fcerebrovascular disease within 6 months prior to screening, defined as: ① Myocardial infarction (MI) or unstable angina; ② Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention); ③Congestive heart failure (New York Heart Association \\[NYHA\\] Class III-IV) (see Appendix 3); ④ Cerebrovascular accident (except old lacunar infarction), including but not limited to stroke\u002Ftransient ischemic attack; ⑤ Other cardiovascular or cerebrovascular diseases deemed unsuitable for trial participation by the investigator;\n7. Retinal diseases requiring urgent treatment at screening (including but not limited to retinal vascular disorders, retinal inflammation, retinal detachment, retinal degeneration, etc.), as assessed by the investigator;\n8. History of severe hypoglycemic coma or frequent hypoglycemia (≥1 episode\u002Fweek) within 2 months prior to enrollment (defined as fingertip or venous blood glucose \\\u003C3.9 mmol\u002FL for T2DM subjects or \\\u003C2.8 mmol\u002FL for non-T2DM subjects);\n9. Gastroparesis or other gastrointestinal motility disorders (e.g., pyloric obstruction, intestinal obstruction, etc.), uncontrolled gastroesophageal reflux disease, or gastrointestinal conditions deemed by the investigator to increase drug-related risks (e.g., severe active ulcers, inflammatory bowel disease, acute gastroenteritis, symptomatic chronic gastritis, functional gastrointestinal disorders, intestinal tuberculosis, etc.);\n10. Major surgery, severe trauma, or severe infection within 1 month prior to screening, deemed unsuitable for participation by the investigator;\n11. History of malignancy (except adequately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer post-radical therapy, ductal carcinoma in situ of the breast post-radical therapy, and papillary thyroid carcinoma post-radical therapy);\n12. Concurrent diseases deemed by the investigator to affect subject safety, efficacy evaluation, or compliance, e.g., neurological, endocrine, psychiatric, etc. ; 4.Laboratory abnormalities at screening meeting any of the following criteria:\n\n1\\) Hepatic or renal impairment, based on each hospital laboratory's reference values, serum ALT and\u002For AST \\>5× upper limit of normal (ULN); serum total bilirubin ≥1.5×ULN; estimated glomerular filtration rate (eGFR) \\\u003C60 mL·min-1·1.73m-2. (calculated using CKD-EPI formula see Appendix 4) ; 2) Alkaline phosphatase (ALP) \\>2.0×ULN; 3) Platelet count \\\u003C 100 × 10⁹\u002FL; 4) Serum calcitonin ≥ 50 pg\u002FmL (i.e., 50 ng\u002FL); 5) Serum amylase or lipase \\> 2.0× ULN; 6) International normalized ratio (INR) \\>1.2×ULN at screening; 7) Albumin \\\u003C 3.5 g\u002FdL (35.0 g\u002FL). 8) Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg at screening), subjects may be re-screened after 1 month of initiating or adjusting antihypertensive therapy; 9) Unstable thyroid dysfunction requiring medication adjustment at screening, or clinically significant abnormal thyroid function test results necessitating treatment initiation; 10) Subjects with clinically significant ECG abnormalities at screening, including: a) Second- or third-degree atrioventricular block; b) Long QT syndrome, QTcF \\>470 ms for females or \\>450 ms for males (QTcF = QT\u002F(RR\\^0.33) ); c) Wolff-Parkinson-White syndrome; or d) Other severe arrhythmias requiring treatment; 11) Abnormal physical examination, vital signs, or laboratory results deemed clinically significant by the investigator, potentially posing major risks or interfering with efficacy, safety, or PK evaluations; 5.Contraindications to liver biopsy at screening, as assessed by the investigator:(1) Hepatic hemangioma or hepatic alveolar echinococcosis;(2) Extrahepatic obstructive jaundice;(3) Significant bleeding tendency, severe thrombocytopenia, or coagulation disorders;(4) Coma or uncooperative due to other conditions;(5) Infection at the puncture site; 6.Positive for hepatitis B surface antigen, positive for hepatitis B core antibody (except those with positive anti-HBc but hepatitis B virus deoxyribonucleic acid \\[HBV-DNA\\] below the lower limit of the reference range), positive for hepatitis C virus antibody with hepatitis C virus ribonucleic acid (HCV-RNA) above the upper limit of the reference range (subjects with a history of HCV infection may be enrolled if HCV PCR has been negative for more than 3 years), positive for human immunodeficiency virus antibody, or positive for syphilis antibody (except cured syphilis) will be excluded; 7.Blood loss or donation \\> 400 mL within 3 months prior to screening, receipt of blood\u002Fcomponent transfusions; or concurrent hemoglobinopathy, hemolytic anemia, or sickle-cell disease.\n\n8.MRI contraindications, including but not limited to severe claustrophobia, large tattoos, inner ear implants, pacemakers or other implantable rhythm management devices, MRI-incompatible intracranial aneurysm clips, or other non-MRI-compatible metal implants (e.g., insulin pumps, hip replacements); 9.Participation in other clinical trial within 3 months prior to screening or 5 half-lives of the investigational drug (whichever is longer)(except for screening-only or non-interventional studies): 10.Excessive alcohol consumption within 12 months prior to screening, defined as \\>210 g\u002Fweek (male) or \\>140 g\u002Fweek (female) of ethanol (alcohol) for \\>3 months. Ethanol intake \\[g\\] = volume \\[mL\\] × alcohol percentage × 0.8); 11.Lactating or pregnant females; 12.Intolerance to venipuncture or history of needle\u002Fphobia; 13.Other conditions deemed unsuitable for trial participation by the investigator.",{"count":117,"type":22},156,[119],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose，6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.",[122],"Metabolic Dysfunction-associated Steatohepatitis (MASH)","RECRUITING","2025-11-19",{"date":126,"type":33},"2025-11-20",{"date":128,"type":33},"2025-09-30",{"date":130,"type":22},"2027-08-31",{"name":39,"class":40},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":41},"100603270","phase-2-ubt251-injection-phase-ii-clinical-study-ckd-100603270","NCT07134335","UBT251 Injection Phase II Clinical Study (CKD)","A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese\u002FOverweight Chronic Kidney Disease (CKD) Population","Inclusion Criteria:\n\n1. Age 18\\~75 years old (including border value), BMI \\>=24 kg\u002Fm\\^2, gender is not limited.\n2. Subject estimated glomerular filtration rate (eGFR): \\>=45 and \\\u003C 90 mL\u002Fmin\u002F1.73m\\^2 (calculated using the CKD-EPI formula).\n3. Subjects 300 mg\u002Fg \\\u003C= UACR \\\u003C= 5000 mg\u002Fg 3 months or more prior to screening; At least 2 measurements (not on the same day) within 4 weeks of the screening period, and each measurement must meet this criterion.\n4. If treated with SGLT2i, angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs) before screening, a stable dose of \\>=4 weeks is required unless there are contraindications or intolerance. (For subjects who are intolerant to the above drugs, they can still be included if judged by the investigator to be suitable to participate in the investigator.) )\n5. Volunteer to participate in the study and sign the ICF.\n6. Female of childbearing potential or male subjects with partners of childbearing potential agree to use effective contraception from the start of study treatment until 3 months after the end of the last dose.\n\nExclusion Criteria:\n\n1. History or evidence of any of the following diseases: 1) Diagnosis of type 1 diabetes or other special type diabetes. 2) Presence of non-recovered acute kidney injury (AKI) at screening. 3) Previous or current suffering: bilateral renal artery stenosis (stenosis\\>=50%), tubulointerstitial nephritis, lupus nephritis, autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, unilateral nephrectomy or other severe renal structural abnormalities, and a history of unstable or rapidly progressing kidney disease as judged by the investigator. 4) Poorly controlled hypertension (systolic blood pressure \\>=160 mmHg and\u002For diastolic blood pressure \\>=100 mmHg at screening). 5) Glycated hemoglobin (HbA1c) \\>= 9.5%. 6) Presence of serious illness or medical condition judged by the investigator during the screening period, including but not limited to: a) History of malignant tumor disease within 5 years prior to screening (except for cured basal cell or squamous cell carcinoma of the skin and carcinoma in situ at any site); b) Arterial\u002Fvenous thrombotic events within 6 months prior to screening, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction \\[except old lacunar cerebral infarction\\]), deep vein thrombosis; c) History of internal myocardial infarction or surgery such as percutaneous coronary intervention and coronary artery bypass grafting 6 months before screening; d) History of internal heart failure 6 months prior to screening, with New York Heart Association (NYHA) functional class III. or IV. 7) Combined with gastroparesis or other diseases related to gastrointestinal emptying disorders (such as pyloric obstruction, intestinal obstruction, etc.), uncontrolled gastroesophageal reflux disease, gastrointestinal diseases assessed by the investigator as increasing the risk after medication (such as severe active ulcers, inflammatory bowel disease, acute gastroenteritis, symptomatic chronic gastroenteritis), or undergoing major upper gastrointestinal surgery. 8) History of pancreatitis or pancreatic injury, or pancreatic surgery. 9) History of symptomatic gallbladder disease within 2 years prior to screening, defined as imaging examination suggesting the presence of gallstones and diagnosis-related symptoms related to gallstones; Subjects who have undergone gallstone surgery and\u002For cholecystectomy (surgery completed at least 3 months prior to screening) with no long-term complications may participate in this study. 10) History or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia (MEN) type 2. 11) History of acute complications of diabetes (diabetic ketoacidosis, diabetic lactic acidosis, hyperglycemic hyperosmolar state, etc.) within 6 months prior to screening. 12) Severe retinal and macular degeneration (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) in the past or at screening, which require further urgent treatment as judged by the investigator. 13) Severe chronic complications of diabetes (including but not limited to severe diabetic neuropathy, diabetic foot, etc.) at screening, and the investigator judges that this complication may affect the compliance and safety of the subjects. 14) Severe hypoglycemia or recurrent symptomatic hypoglycemia within 6 months prior to screening (\\>=2 times within half a year). 15) Abnormal thyroid function that cannot be controlled with a stable dose of medication, or clinically significant abnormalities in thyroid function test results at screening that require initiation of treatment; 16) History of depression or patient health status questionnaire-9 (PHQ-9) score \\>=15 points at screening; or a history of severe mental illness (including but not limited to suicidal tendencies or suicide attempts, schizophrenia, bipolar disorder, etc.).\n2. Medication history within 3 months prior to randomization that meets any of the following conditions: 1) Receive dipeptidyl peptidase 4 (DPP-4) inhibitors, amylin analogues, glucagon-like peptide-1 (GLP-1) analogues, glucose-dependent insulinic polypeptide (GIP) analogues, glucagon (GCG) analogues. 2) Systemic use of steroid glucocorticoids or immunosuppressants (except for topical or intraarticular, intranasal, and inhaled glucocorticoids; Short-term \\[\\\u003C= 7 days\\] use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases). 3) Use of over-the-counter weight loss drugs (including but not limited to orlistat) or food inhibitors (including traditional Chinese medicine), or treatment with lipid-dissolving injections (e.g., lipolysis injections) within 3 months prior to screening.\n3. Those who have any of the following test abnormalities during screening: 1) Severe anemia (hemoglobin \\\u003C 7.0 g\u002FdL); 2) Abnormal liver function (ALT or AST \\>= 3 ×upper limit of normal \\[ULN\\], or serum total bilirubin \\[TBIL\\] \\>= 1.5 × ULN); 3) Serum albumin \\\u003C 30 g\u002FL; 4) Serum potassium \\> 5.5 mmol\u002FL; 5) Fasting triglycerides \\>= 5.6 mmol\u002FL; 6) International normalized ratio (INR) \\>= 1.5 × ULN; 7) Serum calcitonin level \\> 50 ng\u002FL; 8) Serum amylase or lipase \\> 2.0× ULN. 9) Positive hepatitis B surface antigen (HBsAg) test and hepatitis B virus deoxyribonucleic acid (HBV-DNA) higher than the lower limit of detection, positive hepatitis C virus antibody test (HCV-Ab) and hepatitis C virus ribonucleic acid (HCV-RNA) above the upper limit of the reference value range, positive human immunodeficiency virus antibody (HIV-Ab) test at screening, syphilis antibody (TP- Ab) Those who test positive (RPR titer or TRUST test is required, except for cured syphilis). 10) Clinically significant electrocardiogram (ECG) abnormalities at screening (meeting one of them): a) Second or third degree atrioventricular block; b) Long QT syndrome; or QTcF \\> 470ms for women and \\> 450ms for males；c) pre-excitation syndrome; d) Other severe arrhythmias requiring treatment; e) Heart rate \\\u003C 50 beats\u002Fmin or \\> 110 beats\u002Fmin.\n4. Body weight change of more than 5% within 6 weeks prior to screening.\n5. Those who have had or plan to undergo bariatric surgery during the trial.\n6. Those with a history of alcohol and drug abuse.\n7. Those who are allergic to the study drug or its excipients.\n8. Those who have participated in other clinical trials within 30 days before screening (except for screening only but not medicated or non-interventional studies) or within 5 half-lives of using investigational drugs, whichever is longer.\n9. Subject is receiving dialysis\u002Fkidney transplantation or plans to undergo dialysis\u002Fkidney transplantation during the study.\n10. Pregnant or lactating women.\n11. Other conditions that the investigator considers unsuitable for participation in the study.",{"count":140,"type":22},180,[119],"This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese\u002Foverweight chronic kidney disease (CKD) population",[144,145],"Obesity &Amp; Overweight","Chronic Kidney Disease",{"date":147,"type":33},"2025-11-25",{"date":149,"type":33},"2025-09-01",{"date":151,"type":22},"2030-07-11",{"name":39,"class":40},""]